Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model

PURPOSE: In this study, a therapeutic drug monitoring (TDM) of erlotinib in pancreatic cancer patients was performed over 50 weeks to reveal possible alterations in erlotinib plasma concentrations. Additionally, a physiologically based pharmacokinetic (PBPK) model was created to assess such variatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruber, Andrea, Czejka, Martin, Buchner, Philipp, Kitzmueller, Marie, Kirchbaumer Baroian, Nairi, Dittrich, Christian, Sahmanovic Hrgovcic, Azra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854746/
https://www.ncbi.nlm.nih.gov/pubmed/29453635
http://dx.doi.org/10.1007/s00280-018-3545-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854746/
https://www.ncbi.nlm.nih.gov/pubmed/29453635
http://dx.doi.org/10.1007/s00280-018-3545-4

Ejemplares similares